Heptares to Present at UBS Global Healthcare Conference and Upcoming Scientific Events

LONDON and BOSTON, May 15, 2014 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, will give a company presentation at the UBS Global Healthcare Conference in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 19 May.

In addition, senior scientists from Heptares will give scientific presentations at the following industry meetings over the coming weeks:

The 34^th National Medicinal Chemistry Symposium (Charleston, SC, USA, 18-21 May)

Dr John Christopher, Heptares' Associate Director Chemistry, will present "Case Studies in GPCR Drug Design" at 1:30pm EDT on Wednesday 21 May.

14^th Annual Structure-Based Drug Design (Boston, MA, USA, 21-22 May)

Dr Jon Mason, Heptares' Head of Computational Chemistry will present "High End GPCR Design: Crafted Ligand Design and Druggability Analysis Using Protein Structure, Lipophilic Hotspots and Explicit Water Networks" at 2:05pm EDT on Wednesday 21 May.

GTC GPCR Structure, Function and Drug Discovery (Boston, MA, USA, 22-23 May)

Dr Jon Mason will present "Structure Based Drug Discovery Applied to GPCRs" at 1:15pm EDT on

Thursday 22 May.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics 

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;  

StaR is a registered trademark in the EU and Japan. 

SOURCE Heptares Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED